FAM160B1

Across TCGA pan-cancer cohorts, FAM160B1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FAM160B1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FAM160B1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM160B1 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

HNSC, SCLC, and ESCA are the cancer types where FAM160B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.219	0.660	.007	27	view →
SCLC	OS	Median	III,IV	0.055	0.640	<.001	12	view →
ESCA	DFS	Median	II,III,IV	0.089	0.522	.001	12	view →
BLCA	DFS	Median	All	0.870	0.325	.025	9	view →
UCEC	DFS	Median	All	0.973	0.827	.016	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.667	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FAM160B1–HNSC (OS)

Open the HNSC breakdown →